HOPA

Articles

Among somatic mutations, approximately 89% of patients with metastatic castration-resistant prostate cancer have a potentially actionable mutation.

Assessing Germline, Somatic Genetic Testing for Prostate Cancer

Hematology/Oncology Pharmacy Association plans to develop tools and resources to support those conducting research in the oncology pharmacy field, with the goal of promoting pharmacist-led research and improving the ability to analyze difficult scientific questions.

Incoming HOPA President Outlines Organization’s Future

Patient interactions became vastly different during the pandemic, with questions surrounding how to coordinate contact and how to best provide pharmacy services virtually, including counseling, fielding drug information questions, medication reconciliation, and providing home medication sheets to families

Three Key Areas to Manage in COVID-19 Telehealth Cancer Care Environment

Olaparib and niraparib both show promise in the maintenance treatment of ovarian cancer, though they may each be appropriate for different patient populations. 

Evaluating Single Agent PARP Inhibitors or Combination Therapies for Maintenance Treatment of Ovarian Cancer

Pharmacokinetic differences in pediatric patients should be considered when administering direct oral anticoagulants, as should potential administration difficulties when pellets or oral solutions are not available. 

Direct Oral Anticoagulants Can Minimize IV Treatment in Pediatric Patients

Selection of any BTK inhibitors for mantle cell lymphoma should consider factors such as cardiovascular or bleeding risks, predisposition for gastrointestinal adverse effects, and potential medication nonadherence.

Updates for Second Generation BTK Inhibitors in R/R Mantle Cell Lymphoma

CLL is the most common leukemia in adult patients in the western world, with 21,040 estimated new cases in 2020. 

Updates in Front-Line Treatment of Chronic Lymphocytic Leukemia

For unresectable gastrointestinal stromal tumors, the introduction of imatinib revolutionized treatment. 

Updates in Management of Gastrointestinal Stromal Tumors

Urothelial carcinoma is the sixth most common cancer diagnosis in the United States, with an estimated 81,400 new diagnoses in 2020 and 17,980 deaths. 

Erdafitinib, Enfortimab Vedotin Offer New Treatments for Metastatic Urothelial Carcinoma

Oral chemotherapies can be effective treatments for children with low-grade gliomas, although clinicians should consider available formulations and administration schedules. 